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Introduction
More than 99% of cervical cancers are associated with the
human papilloma virus (HPV). In these HPV-associated
tumours, two viral proteins remain expressed, E6 and E7.
The development of vaccines and immunotherapies
against cervical tumours targeting these viral oncoproteins
has been documented to be effective and highly immuno-
genic (Roden and Wu 2006; Kim et al. 2008). Immuniza-
tion with E7 has been shown to cause specific therapeutic
effects against established E7-expressing tumours in mice
(Kim et al. 2007). Even though the use of this viral pro-
tein as immunotherapy against cervical cancer was shown
to be specific and effective, it possesses an undesired char-
acteristic. This unfavourable condition is that E7 main-
tains its transforming activity (Shi et al. 1999). This
inconvenience was overcome by the modification of two
repeating Cys-X-X-Cys sequence motifs at the carboxyl
terminus of E7 in the CR3 domain containing residues
58–61 and 91–94 with repeating cysteines, which is neces-
sary for the formation of a zinc finger, an important struc-
ture that gives stability to the E7 protein. The inability of
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Abstract
Aims: To create and provide a strain of the food-grade bacterium Lactococcus
lactis able to efficiently secrete a modified form of the E7 protein from the
human papilloma virus (HPV) type-16.
Methods and Results: We cloned the coding sequence of a modified E7 (E7m)
from the HPV-16 in a plasmid regulated by the strong expression promoter
p59. Secretion of the E7m was made by the signal peptide of the usp45 gene.
The E7m was detected by Western blot in the cell-free-medium fraction, show-
ing no degradation or aberrant forms.
Conclusions: We constructed a strain of L. lactis able to secrete efficiently a
HPV-16 E7 modified protein with diminished transforming activity.
Significance and Impact of the Study: Human papilloma virus infection is
associated with more than 99% of cervical cancers. Immunotherapy targeting
E7 to treat HPV-associated cervical malignancies has been demonstrated to be
highly efficient. However, native E7 maintains transforming activity. We pres-
ent this new strain of a food-grade bacterium able to efficiently secrete a
HPV-16 E7-modified protein with diminished transforming activity. This new
strain could be used as a live vaccine to deliver E7 at a mucosal level and
generate antitumour immune responses against HPV-associated tumours.
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this modified E7 to form this particular structure dramati-
cally diminishes its transforming activity in cultures
in vitro of murine and human cells (McIntyre et al. 1993).
It has been demonstrated that this modified E7 is
degraded rapidly by the proteosome and that a greater
amount of antigenic peptides are being transported to the
endoplasmatic reticulum and presented to antigen-pre-
sented cells (APCs) (Shi et al. 1999). Moreover, this mod-
ified E7 with altered motifs has a reduced ability to
transform a variety of rodent fibroblasts, fails to immor-
talize human keratinocytes, and exhibits a lower transacti-
vating efficiency (McIntyre et al. 1993). Immunization
with this modified E7 caused stronger protection immu-
nity against E7-expressing cell lines than the wild-type E7
(Shi et al. 1999).
For years, the use of L. lactis to produce and deliver
heterologous proteins of medical interest has been dem-
onstrated to be efficient and innocuous (Wells and
Mercenier 2008). The intranasal immunization with this
food-grade bacterium expressing antigens has resulted in
the generation of specific protective and therapeutic
responses against infectious and chronic diseases (Hann-
iffy et al. 2007; Wells and Mercenier 2008). We have con-
structed a strain of the lactic acid bacterium (LAB)
L. lactis able to secrete a modified E7 of the HPV that
may be used as a live vaccine against the HPV-16 and
tumours associated with this virus.
Materials and methods
Bacterial strains and growth conditions
Escherichia coli DH5a was grown aerobically in Luria
Bertani broth at 37C with vigorous agitation. The L. lac-
tis strain MG1363 was grown aerobically in M17 broth
supplemented with 0Æ5% glucose (GM17) at 30C without
agitation. Selection of clones was carried out by the addi-
tion of 100 lg ml)1 of ampicillin for E. coli and
75 lg ml)1 of erythromycin for L. lactis. All constructions
were first established in E. coli and then transferred to
L. lactis by electrotransformation using the method previ-
ously described (Holo and Nes 1989). Plasmid DNA iso-
lation, DNA manipulation, and PCR were carried out
essentially as described (Sambrook et al. 1989).
Protein extraction from L. lactis
Cell and cell-free-medium fractions were prepared sepa-
rately. Samples were processed from 1Æ35 ml of the culture.
Cell pellets were obtained by centrifugation at 21000 g
at 4C for 5 min, and the pellets resuspended in 100 ll
of TES-lysis buffer (25% sucrose, 1 mmol l)1 EDTA,
50 mmol l)1 Tris.HCL [pH 8Æ0], lysozyme [10 mg ml)1]
complemented with 1 mmol l)1 phenylmethylsulfonylfluo-
ride (PMSF), and 10 mmol l)1 of dithiothreitol). The
mixture was incubated at 37C for one h, and then 50 ll
of 20% SDS and one volume of loading buffer were added.
The samples were maintained at )20C before loading
onto the gel.
The cell-free-medium samples were treated with
1 mmol l)1 of PMSF and 10 mmol l)1 of dithiothreitol to
avoid proteolysis. Proteins were precipitated using 150 ll
of 100% trichloroacetic acid (TCA) and incubated on
ice for 10 min, then followed by centrifugation at 21000 g
at 4C for 15 min. The pellet was resuspended in 50 ll
of 50 mmol l)1 NaOH and 50 ll of SDS-PAGE loading
buffer (100 mmol l)1 Tris.HCl, [pH 6Æ8], 200 mmol l)1
dithiothreitol, 4% SDS, 0Æ1% bromophenol blue, and
10% glycerol).
SDS-PAGE and Western blotting
One-fifteenth of the whole cell extracts and one-fifth of
the cell-free-medium fractions from 1Æ35 ml culture were
loaded onto 12% acrylamide gels. SDS-PAGE and
Western blotting were carried out essentially as described
(Sambrook et al. 1989). Immunodetection of E7 was
carried out by the use of monoclonal anti-E7 (Santa Cruz
Biotechnology, Santa Cruz, CA) as a primary antibody
and protein-G horseradish peroxidase conjugate (Bio-
Rad, Hercules, CA) and the SuperSignal West Pico
Chemiluminescent Substrate kit (Thermo Scientific
Pierce, Rockford, IL) as recommended by the suppliers.
Coomassie Blue staining
Twelve per cent SDS-PAGE gels with electrophoresed
protein samples were submerged in CBB Buffer (0Æ1%
Coomassie Brilliant Blue R-250, 20% methanol, 0Æ5% ace-
tic acid) overnight. The gel was incubated in destaining
buffer (40% methanol, 7% acetic acid) for 2 h at room
temperature with mild agitation.
Results
Generation of an expression system to secrete the
modified E7 by L. lactis
The modified-E7 DNA coding sequence was PCR-ampli-
fied from plasmid BC219-E7 (kindly donated by Dr Liang
Qiao) using oligos SalI-Fw 5-AGTCGACCCATTGCATG
GAGATACACCTACATTG-3 and TER-Rv 5-ATCAAAA
AAAAGCCCGCTCATTAGGCGGGCTATTTATGGTTTC
TGAGAACAGA-3. SalI-Fw oligo generated a SalI restric-
tion site in the E7 amplicon (underlined) at the 5¢ ter-
mini that allowed the cloning of the E7m sequence
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in-frame with the signal peptide of usp45, the most
secreted protein of L. lactis (van Asseldonk et al. 1990).
The TER-Rv oligo generated a rho-independent transcrip-
tion terminator for clone stability (underlined) and a stop
codon (in bold). Amplicons were directly cloned into
pGEM-T Easy Vector (Promega, Madison, WI) and then
digested with SalI-SpeI sequentially. The fragment corre-
sponding to E7m was subcloned in the pVE-5524 vector
cut with the same enzymes. This new plasmid (pSEC-
E7m) has controlling sequences to allow expression and
secretion of E7m under the regulation of the high expres-
sion and constitutively active promoter p59 (Fig. 1). The
pSEC-E7m was introduced into the L. lactis strain
MG1363 by electroporation. Clones were selected by the
resistance to erythromycin. This newly constructed strain
of L. lactis was named Ll-pSEC-E7m. All constructs were
characterized by endonuclease restriction analysis and
PCR and sequenced to verify DNA integrity.
Secretion of E7m by L. lactis
Detection of E7m by Coomassie blue staining. To evaluate
the ability of the strain Ll-pSEC-E7m to secrete E7m,
protein extracts from cell and cell-free-medium fractions
were made from cultures of our recombinant strain. For
this, we allowed cultures of the Ll-pSEC-E7m to reach an
OD600nm of one. From each culture, 1Æ35 ml was centri-
fuged at 17000 g for five min at 4C to separate bacteria
and the cell-free medium. The cell-free medium was fil-
tered through a 0Æ22-lm pore-diameter (Milipore, Biller-
ica, MA) filter to remove the remaining bacteria. The
total proteins were precipitated with TCA (for more
details, see materials and methods). Samples from the cell
fractions of L. lactis were prepared as well. After electro-
phoresis, acrylamide gels were stained with Coomassie
Blue to visualize total proteins from the cell- and cell-
free-medium protein extracts from cultures of L. lactis.
Figure 2a shows the electrophoresed L. lactis protein
samples from the strains transformed with an empty vec-
tor (pSEC) and our recombinant strain Ll-pSEC-E7m.
Samples from the cell-free medium of our recombinant
strain revealed the secretion of a distinctive protein band
that corresponds to the expected size of the E7m (indi-
cated with asterisk in Fig. 2a). This particular protein
band is absent in the cell-free-medium samples from
L. lactis transformed with the empty vector pSEC (lacking
the E7m-coding sequence) and in whole cell-extract sam-
ples from both strains. The stain intensity of this secreted
protein is close in amount to the major lactococcal
secreted protein Usp45 (indicated by a double asterisk in
Fig. 2a).
Detection of E7m by Western blot. To determine whether
the secreted protein band seen in the SDS-PAGE protein
gel corresponds to the protein E7, a duplicated gel from
Fig. 2a was analysed by immunoblotting using a mouse
monoclonal anti-E7 (Santa Cruz). Western blot analysis
revealed a single clear band in the sample from the cell-
free cultures of our recombinant strain Ll-pSEC-E7m cor-
responding to the expected size of E7m (Figure 2b).
Moreover, no signal was detected in the whole cell frac-
tion of this recombinant strain, meaning that the secre-
tion of E7m was achieved successfully and that no
protein remained inside the cell. As expected, no signal
was detected in either of the samples from cell-free cul-
tures or cell fractions of L. lactis wild-type (data not
shown) or in L. lactis transformed with an empty vector
(pSEC) with no E7m coding sequence (Fig. 2b).
Discussion
The E7 protein of the HPV has been demonstrated to be
a good target to develop both prophylactic and therapeu-
tic tumour vaccines (Roden and Wu 2006; Kim et al.
2008). Immunization with this antigen has been demon-
strated to cause a specific, cytotoxic immune response
against tumours expressing E7. An adverse side effect of
this is that E7 maintains its transforming activity, increas-
ing the risk of cellular transformation.
We made a strain of the food-grade bacterium L. lactis,
a lactic acid bacterium (LAB), able to secrete a modified
E7 from the HPV type-16. To address the E7m outside
the cell, we made use of the signal peptide from the
usp45 protein, which is the most secreted protein of
L. lactis (van Asseldonk et al. 1993).
Western blot analysis using specific monoclonal anti-
bodies corroborated the highly efficient secretion of E7m
by L. lactis. Only one strong signal corresponding to E7m
was detected in the cell-free-medium sample of the
recombinant lactococcus. The absence of signal in the
whole-cell extract sample means that the E7m protein
was efficiently processed and secreted by this recombinant
lactococcus.
p59 RBS USP45 E7m Ter 
Figure 1 Expression cassette for E7m secretion by L. lactis. Coding
sequence of E7m was placed under control of the high-expression
constitutive p59 promoter (stripped bar), the ribosome binding site
(RBS) indicated in the empty bar, and the signal peptide of usp45
from L. lactis. The grey bar (Ter) represents a rho-independent trpA
transcription terminator fused just downstream to the E7m gene.
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The secreted protein identified as E7 by Western blot
corresponds to the Coomassie-Blue-stained protein shown
in the SDS-PAGE gels. It is noteworthy to compare the
intensity of this E7m band (indicated with an asterisk in
Fig. 2a) with that of the usp45, which is the major pro-
tein secreted in L. lactis (indicated with a double asterisk).
In this work, we used the usp45 secretion signal to secrete
our E7m. Both the usp45-protein bands, from strains
transformed with an empty vector (with no E7m coding
DNA sequence) and the recombinant transformed with
the vector coding for E7m, were similar in intensity. This
outcome indicates how a heterologous protein expressed
by L. lactis using an endogenous-signal peptide may be
secreted in the same manner and undergo the same
processing as the native protein from which the signal
peptide was used.
Because this strain of L. lactis is able to secrete consid-
erable amounts of E7m, it could be used in large-scale
bioreactors to produce E7m in large amounts, with
several benefits including the favourable quality of this
food-grade bacterium that does not produce lipopolysac-
charides or any other toxins.
For years, L. lactis has been used to express heterolo-
gous proteins of medical importance. In 2008, the intra-
nasal immunization with a strain of L. lactis expressing
the PspA antigen of Streptococcus pneumoniae demon-
strated the ability to generate a protective immunity in
mice challenged with this pathogen (Hanniffy et al.
2007). Another strain of L. lactis expressing the interleu-
kin 10 is now in Phase I of clinical trials in humans to
treat the inflammatory bowel disorder Crohn’s disease
(Braat et al. 2006). Because the use of this micro-organ-
ism has been shown to be competent and safe, and more
importantly, to cause specific immune responses against
chronic and infectious diseases, we propose the use of this
new strain of L. lactis able to secrete the E7 of the HPV
for the development of a new live vaccine against cervical
cancer. Further studies will be necessary to confirm the
diminished transforming properties of this modified E7
antigen to cause specific antitumour activity against
HPV-associated tumours and infections with this virus
associated in more than 90% of cervical cancers.
Actogenix and Mucosis (to our knowledge) are the first
two companies offering several vaccines based on L. lactis
expressing immonomodulators and antigens of viral and
bacterial origin to treat pneumonia, mucositis, and influ-
enza. The value of more strains available to make preclin-
ical and clinical trials using L. lactis can provide feasible
and imminent new biopharmaceuticals that can become
commercially available in a short time. This strain, effi-
ciently secreting E7, may be able to determine the thera-
peutic ability to cause specific immune responses against
E7-tumour-bearing organisms, without the transforming
activity of E7 (Audouy et al. 2007; Steidler et al. 2009).
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